Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for adverse events to halt clinical trials and regulatory approvals [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Sarepta investors affected by alleged securities fraud between June 22, 2023, and June 24, 2025 [1]. - The complaint claims that Sarepta made false statements regarding ELEVIDYS, including significant safety risks, failure to detect severe side effects in trials, and potential regulatory scrutiny due to adverse events [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025 [1] Group 1: Class Action Details - Investors who purchased Sarepta Therapeutics securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [3] - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, which led to significant risks and potential damages for investors [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4] - The firm achieved the largest securities class action settlement against a Chinese company at the time and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]

Core Viewpoint - The complaint against Sarepta Therapeutics alleges violations of federal securities laws due to misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to patient deaths and regulatory scrutiny [2]. Group 1: Safety Concerns and Regulatory Actions - ELEVIDYS is reported to pose significant safety risks, with trial protocols failing to detect severe side effects [2] - Following a patient death on March 18, 2025, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3] - On April 4, 2025, Sarepta halted recruitment and dosing in some clinical studies after EU authorities requested a review of the death, leading to a further stock price decline of $4.18, or 7.13%, to $54.43 [4] - A second patient death due to acute liver failure was disclosed on June 15, 2025, prompting Sarepta to suspend shipments for non-ambulatory patients and pause dosing in one study [5] - Following the second death, Sarepta's stock fell by $15.24, or 42.12%, closing at $20.91 [6] - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the deaths and acute liver failure risks associated with ELEVIDYS, resulting in a stock price drop of $1.52, or 8.01%, to $17.46 [6][7] Group 2: Legal Proceedings and Class Action - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8] - Members of the putative class can choose to serve as lead plaintiff or remain absent without affecting their ability to share in any recovery [8] - Faruqi & Faruqi, LLP encourages individuals with information regarding Sarepta's conduct to come forward, including whistleblowers and former employees [9]

Financial Data and Key Metrics Changes - The net loss for Q3 2025 was $175.2 million, or a loss of $1.26 per share, compared to a net loss of $170.8 million, or a loss of $1.38 per share in Q3 2024 [35] - Revenue for Q3 2025 was $27.8 million, primarily from the collaboration agreement with Sarepta, with $20 million from initial consideration and $7 million from reimbursement of collaboration costs [35][36] - Total operating expenses for Q3 2025 were $193.3 million, an increase from $176.1 million in the prior year, driven by higher R&D costs and SG&A expenses [37][38] - Cash and investments totaled $900.4 million as of June 30, 2025 [38] Business Line Data and Key Metrics Changes - The company achieved full enrollment in Phase 3 studies for clozaran, targeting severe hypertriglyceridemia, with approximately 2,200 patients enrolled across 24 countries [9][24] - The Phase 3 study for zodasiran began with the first patients enrolled in July 2025, targeting homozygous familial hypocholesterolemia [10][27] - The company is on track to meet its 2025 initiative of having 20 individual drug candidates in clinical studies or at market, with nine partnered and 11 wholly owned candidates [16] Market Data and Key Metrics Changes - The collaboration with Sarepta is expected to continue, providing capital to fund internal programs, despite Sarepta's recent setbacks [6] - The company is preparing for the US launch of clozaran, with a PDUFA date set for November 18, 2025, and has engaged with payers representing over 85% of US covered lives [29][30] Company Strategy and Development Direction - The company aims to create value through novel medicines, generate capital for development, and build a growth engine [7] - The focus is on expanding the cardiometabolic franchise and addressing unmet medical needs in various patient populations [14][31] - The company is building a commercial organization to support the launch of its products, particularly clozaran and zodasiran [21][40] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging biotech market but emphasized their commitment to serving patients and creating shareholder value [7] - The company is optimistic about the upcoming regulatory submissions and the potential for multiple product launches between late 2025 and 2028 [12][16] - Management expressed confidence in the collaboration with Sarepta and the potential for significant future milestones [6][36] Other Important Information - The company has made significant progress in sourcing new capital, including a $130 million upfront payment from Sanofi for rights to develop clozaran in Greater China [18][36] - The company expects to achieve a $100 million milestone payment from Sarepta and anticipates a second milestone of $200 million by the end of the year [36][38] Q&A Session Summary Question: How does the company view competitors' programs in triglyceride reduction? - Management stated that they focus on their own studies and have had positive data in their Phase 2 and Phase 3 studies, expecting to demonstrate best-in-class triglyceride reduction [44][46] Question: What are the baseline demographics for the Phase III studies? - Management confirmed that their baseline demographics are similar to those published by competitors, but emphasized the importance of focusing on adjudicated cases of pancreatitis rather than abdominal pain [52][56] Question: How does clozaran address unmet clinical needs? - Management highlighted that clozaran offers deep triglyceride reduction and is the only agent in a registrational Phase 3 study that has shown a statistically significant reduction in acute pancreatitis risk [61][62] Question: What is the expected pricing strategy for clozaran? - Management indicated that they expect clozaran to be priced higher than treatments for severe hypertriglyceridemia, but specific pricing details are still under consideration [65] Question: What is the expected timeline for the auto-injector for clozaran? - Management stated that the initial presentation will be a prefilled syringe, with development underway for an auto-injector expected to be available at launch or soon thereafter [88][89]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [3]. - Specific claims include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to halted recruitment and increased regulatory scrutiny [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered due to deceit and illegal business practices [5]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Insights - Sarepta Therapeutics, Inc. (SRPT) reported a second-quarter 2025 adjusted EPS of $2.02, significantly exceeding the Zacks Consensus Estimate of $1.11, primarily due to higher collaboration revenues and lower operating expenses [1][9] - Total revenues reached $611.1 million, marking a 68% year-over-year increase, driven by sales of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), which also surpassed the Zacks Consensus Estimate of $529.5 million [2][9] Financial Performance - Adjusted EPS of $2.02 compared to 43 cents in the same quarter last year, while including depreciation and amortization, the EPS was $1.89 compared to 7 cents previously [1][2] - Product revenues increased by 42% year over year to $513.1 million, with Elevidys sales contributing significantly [3][4] - Elevidys sales alone generated $281.9 million, a 132% increase year over year, exceeding estimates [4][5] Collaboration and Revenue Streams - Collaboration revenues associated with Elevidys amounted to approximately $98.0 million, including a $63.5 million milestone payment from Roche for Elevidys approval in Japan [5][6] - The licensing agreement with Roche grants exclusive rights to market Elevidys in non-U.S. markets [6] Operating Costs - Adjusted R&D expenses totaled $181.7 million, an 18% increase year over year, reflecting higher clinical material expenses for Elevidys [7] - Adjusted SG&A expenses rose 7% to $113.4 million, driven by increased professional service expenses related to Elevidys marketing efforts [7] Future Guidance - The company expects to generate around $900 million from its three PMO therapies in 2025 [12] - Management anticipates minimum annual revenues of $500 million from Elevidys infusions in the ambulant population for the full year [11] Pipeline and Restructuring - Sarepta is addressing safety concerns related to patient deaths linked to its gene therapies and is developing a new protocol for safer administration in non-ambulatory patients [13][18] - A restructuring plan aims to save nearly $400 million annually starting in 2026, including a workforce reduction of 36% [19][20] - The company has shifted focus to siRNA programs acquired from Arrowhead Pharmaceuticals, pausing most of its LGMD pipeline development [20][21]

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities [2]. Product Safety Concerns - Elevidys has been alleged to cause fatal acute liver failure in some patients, contradicting Sarepta's claims about the treatment's safety profile [3]. Stock Performance - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price fell by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second patient death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death related to Elevidys was reported on July 17, 2025, resulting in a stock price drop of over 40% on July 18, 2025 [5].

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +81.98%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.35 per share when it actually produced a loss of $3.42, delivering a surprise of -1077.14%.Over the last fo ...

Core Viewpoint - The European Medicines Agency (EMA) recommended the refusal of marketing authorization for Sarepta's ELEVIDYS, leading to a significant decline in the company's stock price [1][2]. Group 1: Regulatory and Clinical Developments - The EMA concluded that ELEVIDYS lacked efficacy, as a key study involving 125 children showed no significant improvement in movement abilities compared to a placebo group [4]. - The EMA's recommendation follows a series of negative events for Sarepta, including patient deaths and a black box warning for acute liver injury and failure on the ELEVIDYS label [2][4]. Group 2: Legal and Financial Implications - A securities class action lawsuit has been filed against Sarepta, alleging that the company made misleading statements regarding the safety and efficacy of ELEVIDYS, which misled investors about its regulatory prospects [5][6]. - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and inadequacies in clinical trial protocols [6]. - The timeline of disclosures includes patient deaths and safety updates that triggered sharp declines in Sarepta's stock price, with the FDA confirming an investigation into acute liver failure risks associated with the drug [7][8][9]. Group 3: Investor Actions and Investigations - Hagens Berman, a national shareholders rights firm, is investigating the legal claims and encourages affected investors to submit their losses [3][11]. - The firm is also seeking information from individuals who may assist in the investigation regarding Sarepta's disclosures and the efficacy of ELEVIDYS [11].